Loading...
•
Sep 30, 2020
Black Diamond Therapeutics Q3 2020 Earnings Report
Reported financial results for Q3 2020 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported $333.1 million in cash, cash equivalents, and investments as of September 30, 2020. The company is progressing with its Phase 1/2 clinical trial of BDTX-189 and strengthened its leadership team with key appointments.
Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021.
Strengthened Board of Directors with appointment of Robert A. Ingram as Chairman.
Bolstered executive team with appointment of Rachel Humphrey, M.D., as Chief Medical Officer.
Cash, cash equivalents, and investments of $333.1 million as of September 30, 2020, expected to be sufficient to fund operations into 2023.
Forward Guidance
The Company will present pre-clinical data on Black Diamond’s GBM program at the Society of Neuro-Oncology 2020 Annual Meeting, taking place November 19-21, 2020 and David M. Epstein, Ph.D., President and CEO of Black Diamond, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 2:40 PM GMT/9:40 AM ET.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...